Renalytix Share Discussion Threads

[mr roper] 07/6/2021 07:34

Yup, looks to be a high calibre group. Time to move the commercialisation up a gear for the next fiscal year. All the right moves being made. Quarterly results should be out later this week.

[wan] 07/6/2021 07:31

Today's news starts to fit with the rebranding, and to attract such a high calibre team with a clear remit to accelerate Renalytix expansion, indeed says a lot about the technology and market opportunity!

There is also a mention of international expansion, and the news also appears to align with Renalytix plans to expand the indicated use of KidneyIntelX for individuals with general chronic kidney disease, which if approved, is expected to increase U.S. total addressable market for KidneyIntelX to an estimated 37 million patients.

[w13ken] 05/6/2021 09:58

It looks like the rebranding is still in progress but it's a good look and there's a new logo, the AI in the name has been dropped and there's a clear mission statement. Seems to be a sign that they are ready to become much wider known.

We are Renalytix.

Our singular goal is to eradicate kidney disease.

[wan] 04/6/2021 09:13

Thanks for the heads-up Mr R an impressive makeover, with a new emphasis on addressing kidney disease, but also monitoring and addressing Kidney health.

And I note an additional TM -

That changes now… with kidney bioprognosis™.

Renalytix is the global founder and leader in the new field of bioprognosis for kidney health. We’ve engineered a new solution that successfully enables early-stage, progression risk assessment, when it counts the most.

[mr roper] 04/6/2021 08:32

Looks like the website has had a slick makeover and rebranding.

hxxps://renalytix.com/

[toffeeman] 03/6/2021 08:22

But a qualitative study only (I think) so just asking about attitudes and it's behavio(u)r that matters.

[mr roper] 03/6/2021 07:08

Good news today. More validation of the impact KidneyIntelX can have on DKD.

[wan] 02/6/2021 17:24

I note todays news after the market closed -


However, quantitative antibody tests have yet to move the dial in terms of volume, and I am not sure it will anytime soon, but it's progress in terms of authorisation (should antibody testing climb up the agenda), plus it does further demonstrate that Kantaro has the expertise and experience in place, which could be applied to other diagnostic tests/innovations -

Kantaro specializes in the rapid scale-up of groundbreaking diagnostic innovations and the creation of partnerships to bring these crucial technologies to market. Kantaro was named one of the World’s Most Innovative Companies by Fast Company in 2021.

[hpcg] 27/5/2021 17:40

US C-suite sales are a different beast. They usually drip feed out programmatically and in any case options refill. Makes it difficult to follow US company news using alerts as for some there is a Form 4 everyday. Also there is something of a difference where the person has a substantial stake from the earliest days rather than simply offloading every new share that comes their way at the earliest opportunity. Don't get me wrong, its better if they keep them, but it isn't a warning sign of anything.

[mr roper] 27/5/2021 17:03

They know it’s good value. This leg should get to $37-$39

[toffeeman] 27/5/2021 17:00

Up 8% stateside

[homebrewruss] 27/5/2021 16:58

psychics? sidekicks?

[toffeeman] 27/5/2021 16:52

Are they septics or sceptics or neither?

[rampmeister] 27/5/2021 16:49

Plus 10% now stateside- do the septics know something?

RM

[little minx] 27/5/2021 16:37

No I bought at just over £10. Just seen the large purchase. I will add on dips.

[someuwin] 27/5/2021 15:57

NASDAQ:RNLX

[toffeeman] 27/5/2021 10:05

>> LM

If you bought in at £1.21 (fundraise oct 2018) then you have a 10-bagger so may wish to take profits

[little minx] 27/5/2021 09:55

Why all the sells

[mr roper] 25/5/2021 10:06

Agree with that, wan. My view is that the management have executed the plan superbly to date. The latest two partnerships seem only just be sinking in Stateside and more and more investors are becoming aware of Renx. Results should be due in the next 10 days. Hopefully we’ll get the first sign of small revenue coming through and it’ll peak the interest of a few more potential investors.
If the management execute to plan my expectation is a $10bn mkt cap in 24 mths, as a result I still think Renx is better value now than at 250p.

NB I looked at exact sciences earlier...$19bn mkt cap..revenue of $1.4bn last year and loss making....
Imagine a scenario of Renx having revenue of $300-500m but the majority dropping to the bottom line in profit...mkt cap...?

[wan] 25/5/2021 09:56

Maybe the following personal story is of relevance?

Many years ago, when I was a relatively naive investor (and I am still learning today!), I learnt what I later believed to be an important lesson.

I owned a share that had risen circa 7-fold to circa £6, which at the time I still saw no reason to sell as the prospects still appeared to be very good to me. However, the CEO sold a relatively large chunk of stock at around the same price (but still held shares), which at the time effectively undermined my rationale to continue to hold and subsequently it shook me (and quite a few other private investors) out the stock entirely, as naively I couldn't understand why he would sell if the prospects were so good? Anyway, I banked a substantial profit.

Post the CEO's sale (and mine) the shares continued to perform quite strongly and eventually the company was bought out at £18 per share. The lesson was that the CEO had sold into strong investor and institutional investor demand, as well as there being the usual personal and regulatory timing matters etc. So, certain insider selling at certain times e.g. when the prospects are good (and guided), and demand is high, can be instructive in perhaps more ways than first impressions imply.

Some would say that it's never wrong to take a profit, and that I should have sold only part of my holding, yes may be, and hindsight is a wonderful thing, but I believe I did learn from that experience.

My main thrust is that taking a profit can be wrong, just as taking a loss can be right, and there is probably no absolute catch-all practice that is guaranteed to work. But I would suggest that the managements track record in delivering value to shareholders is as good as anything, and EKF and Renalytix investors have had that delivered in spades! Importantly, there are strong indications to suggest that there is more growth and value creation to come. Readers will get my drift, but investors should of course make up the own minds and arrive at their own conclusions when making investment decisions.

[mr roper] 25/5/2021 09:50

CEO sale was part of a pre agreed trading plan.

[little minx] 25/5/2021 09:26

They would like your shares as bid on each sale slowly increasing.CEO sold a small amount but maybe it was to satisfy a bit of demand.

[wan] 25/5/2021 07:38

I further note the CEO's 'pre-scheduled' sale, into strong demand which of course is not pre-scheduled.

I believe that the current demand is driven by the effective execution and delivery thus far, and importantly, along with the managements guidance on future partnerships and FDA approval etc, which in turn enables the director to not be in possession of material, non-public information, or inside information etc.

Fwiw, My take then, is that ultimately it is a very strong indication, that Renalytix is firmly on schedule to deliver as guided.

[mr roper] 24/5/2021 20:30

The no revenue statement is incorrect. They are generating real world revenue from Q1. Its not material yet, but if it shows increases quarter on quarter this calendar year whilst bringing all of the announced partnerships online growth in the next calendar year could be rapid. As you say, DP, into the 100s of millions quickly.